This study, published in Cancer Immunology Research showed that tumors responding to treatment were enriched in tumor-reactive CD8⁺ T-cell clones expressing high levels of Tim-3, suggesting these cells are key drivers of the anti-tumor response. They also identified differences in myeloid cell differentiation within the tumor microenvironment: in responding tumors, interferon-γ promoted the maturation of monocytes into PD-L1⁺ MHC IIhigh macrophages, whereas in non-responding tumors, this differentiation pathway was impaired.
These findings indicate that both T-cell activity and the dynamics of myeloid differentiation shape the success of PD-1 blockade. Understanding these cellular transitions may help design strategies to improve immunotherapy efficacy and extend its benefits to a larger proportion of patients.